Search
Nelistotug
go.drugbank.com/drugs/DB19334InvestigationalNelistotug is under investigation in clinical trial NCT06062420 (A Platform Study of Novel Immunotherapy Combinations as First-line Treatment in Participants With PD-L1 Positive Recurrent/metastatic Squamous
Tenamfetamine
go.drugbank.com/drugs/DB01509IllicitInvestigationalAn amphetamine derivative that inhibits uptake of catecholamine neurotransmitters. It is a hallucinogen.
5'-Guanosine-Diphosphate-Monothiophosphate
go.drugbank.com/drugs/DB01864ExperimentalA stable GTP analog which enjoys a variety of physiological actions such as stimulation of guanine nucleotide-binding proteins, phosphoinositide hydrolysis, cyclic AMP accumulation, and activation of specific
Imgatuzumab
go.drugbank.com/drugs/DB14884InvestigationalImgatuzumab is under investigation in clinical trial NCT01326000 (A Study of RO5083945 in Combination With FOLFIRI Versus FOLFIRI Plus Cetuximab or FOLFIRI Alone as Second Line Treatment in Patients With
Alobresib
go.drugbank.com/drugs/DB14970InvestigationalAlobresib is under investigation in clinical trial NCT02607228 (Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-5829 as a Single Agent and In Combination With Enzalutamide in Participants
Rocapuldencel-T
go.drugbank.com/drugs/DB17588InvestigationalRocapuldencel-T is an autologous dendritic cell immunotherapy that was investigated in NCT02662634 (A Safety and Feasibility Study of AGS-003-LNG for the Treatment of Stage 3 Non Small Cell Lung Cancer
AVXS-301
go.drugbank.com/drugs/DB17943ExperimentalAVXS-301 consists of an adeno-associated virus serotype 9 (AAV9) designed to express the superoxide dismutase 1 (SOD1) gene.
beta-Naphthoflavone
go.drugbank.com/drugs/DB06732Experimentalβ-Naphthoflavone, also known as 5,6-benzoflavone, is a potent agonist of the aryl hydrocarbon receptor and induces cytochromes P450 (CYPs) and uridine 5'-diphospho-glucuronosyltransferases (UGTs). … It may be a chemopreventive agent.
(+)-Mefloquine
go.drugbank.com/drugs/DB05636Investigational(+)-Mefloquine was under investigation in clinical trial NCT00931697 (Study to Investigate the Safety, Tolerability and Pharmacokinetics of AD 452 [(+)-Mefloquine] Compared With Racemic Mefloquine) to
Canertinib
go.drugbank.com/drugs/DB05424InvestigationalCanertinib treatment significantly affects tumour metabolism, proliferation and hypoxia as determined by PET. … Canertinib is a pan-erbB tyrosine kinase inhibitor which work against esophageal squamous cell carcinoma in vitro and in vivo.
Categories: Compounds used in a research, industrial, or household setting